Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 36 Issue 6
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2018  >  36(6): 547-550

XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
Citation: XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
shu

Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention

doi: 10.3969/j.issn.1006-0111.2018.06.015

  • Department of Clinical Pharmacy, Liuhe Branch of Nanjing Drum Tower Hospital, Nanjing 211500, China;

  • Department of Neurology, Liuhe Branch of Nanjing Drum Tower Hospital, Nanjing 211500, China

  • Received Date: 2018-05-08
  • Rev Recd Date: 2018-09-19
  • Objective To investigate the effect of early intestinal flora intervention on the symptoms and the efficacy of Levodopa and Benserazide in Parkinson's disease (PD), provide a reference for clinical treatment. Methods 114 patients diagnosed as PD for the first time in our department of neurology from January 2015 to October 2017 were randomly divided into intervention group (n=57) and control group (n=57). Both groups received Levodopa and Benserazide, A triple live bacterial preparation was given to the intervention group only to regulate the intestinal flora. Patient-Assessment of Constipation Quality of Life (PAC-QOL) was used to assess the constipation symptoms and patient's satisfaction. The Unified Parkinson's Disease Rating Scale (UPDRS Ⅲ) was used to evaluate the motor symptoms and psychological status for the patients in both groups before and after treatments. Results 1 The PAC-QOL and BSFS scores in intervention group were improved significantly compared to those before treatment (P<0.05); 2 After the treatments, the UPDRS Ⅲ scores in both groups were improved significantly (P<0.05). The UPDRS Ⅲ score in the intervention group was significantly lower than that in the control group at 4 weeks (P<0.05). 3 Compared with the control group, the HAD-A, HAD-D and PSQI Score were decreased in the intervention group. (P<0.05). Conclusion Early intestinal flora intervention effectively alleviated constipation symptom and improved therapeutic effects of Levodopa and Benserazide preparation. However, the long-term effect remains to be studied.
  • [1] BRAAK H, DE VOS R A I, BOHL J, et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology[J]. Neurosci Lett, 2006, 396(1):67-72.
    [2] 中华医学会神经病学分会运动障碍及帕金森病学组.帕金森病的诊断[J].中华神经科杂志,2006,(6):408-409.
    [3] BERG D, POSTUMA RB, ADLER CH, et al. MDS research criteria for prodromal Parkinson's disease[J]. Mov Disord, 2015, 30(12):1600-1611.
    [4] ZHANG TM, YU SY, GUO P, et al. Nonmotor symptoms in patients with Parkinson disease:A cross-sectional observational study[J]. Medicine (Baltimore), 2016, 95(50):e5400.
    [5] ABBOTT RD, PETROVITCH H, WHITE LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease[J]. Neurology, 2001, 57(3):456-462.
    [6] PETROVITCH H, ABBOTT RD, ROSS GW, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death[J]. Mov Disord, 2009, 24(3):371-376.
    [7] KESHAVARZIAN A, GREEN SJ, ENGEN PA, et al. Colonic bacterial composition in Parkinson's disease[J]. Mov Disord, 2015, 30(10):1351-1360.
    [8] FANG X. Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis[J]. Int J Neurosci, 2016, 126(9):771-776.
    [9] NIELSEN HH, QIU J, FRⅡS S, et al. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark[J]. Eur J Neurol, 2012, 19(6):864-869.
    [10] DEVOS D, LEBOUVIER T, LARDEUX B, et al. Colonic inflammation in Parkinson's disease[J]. Neurobiol Dis, 2013, 50:42-48.
    [11] FASAN A, BOVE F, GABRIELLI MA, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease[J].Mov Disord,2013,28(9):1241-1249.
    [12] HOLMQVIST S, CHUTNA O, BOUSSET L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats[J]. Acta Neuropathol, 2014, 128(6):805-820.
    [13] 王文建,郑跃杰.肠道菌群与中枢神经系统相互作用及相关疾病[J].中国微生态学杂志,2016,28(2):240-245.
    [14] ANIL ANANTHASWAMY.Faecal transplant eases symptoms of Parkinson's disease[J].New Scientist,209:8-9.
    [15] BARICHELLA M, PACCHETTI C, BOLLIRI C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease:an RCT[J]. Neurology, 2016, 87(12):1274-1280.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3494) PDF downloads(274) Cited by()

Related
Proportional views

Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention

doi: 10.3969/j.issn.1006-0111.2018.06.015
  • Department of Clinical Pharmacy, Liuhe Branch of Nanjing Drum Tower Hospital, Nanjing 211500, China;
  • Department of Neurology, Liuhe Branch of Nanjing Drum Tower Hospital, Nanjing 211500, China
  • Received Date: 2018-05-08
  • Rev Recd Date: 2018-09-19

Abstract: Objective To investigate the effect of early intestinal flora intervention on the symptoms and the efficacy of Levodopa and Benserazide in Parkinson's disease (PD), provide a reference for clinical treatment. Methods 114 patients diagnosed as PD for the first time in our department of neurology from January 2015 to October 2017 were randomly divided into intervention group (n=57) and control group (n=57). Both groups received Levodopa and Benserazide, A triple live bacterial preparation was given to the intervention group only to regulate the intestinal flora. Patient-Assessment of Constipation Quality of Life (PAC-QOL) was used to assess the constipation symptoms and patient's satisfaction. The Unified Parkinson's Disease Rating Scale (UPDRS Ⅲ) was used to evaluate the motor symptoms and psychological status for the patients in both groups before and after treatments. Results 1 The PAC-QOL and BSFS scores in intervention group were improved significantly compared to those before treatment (P<0.05); 2 After the treatments, the UPDRS Ⅲ scores in both groups were improved significantly (P<0.05). The UPDRS Ⅲ score in the intervention group was significantly lower than that in the control group at 4 weeks (P<0.05). 3 Compared with the control group, the HAD-A, HAD-D and PSQI Score were decreased in the intervention group. (P<0.05). Conclusion Early intestinal flora intervention effectively alleviated constipation symptom and improved therapeutic effects of Levodopa and Benserazide preparation. However, the long-term effect remains to be studied.

XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
Citation: XU Ling, ZHAO Yan, MAO Ling, ZHANG Xihong. Constipation alleviation and the efficacy improvement of levodopa and benserazide in Parkinson patients with early intestinal flora intervention[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 547-550. doi: 10.3969/j.issn.1006-0111.2018.06.015
shu

    HTML

Reference (15)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return